Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 464

1.

Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD.

Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.

Hepatol Commun. 2019 Nov 5;4(1):66-76. doi: 10.1002/hep4.1445. eCollection 2020 Jan.

2.

Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C.

Ogasawara N, Saitoh S, Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 Nov 30. doi: 10.1111/hepr.13467. [Epub ahead of print]

PMID:
31785120
3.

Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver.

Ogasawara N, Saitoh S, Denpou H, Kinowaki K, Akuta N, Suzuki F, Hashimoto M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Fujii T, Kumada H.

Intern Med. 2019 Oct 17. doi: 10.2169/internalmedicine.3577-19. [Epub ahead of print]

4.

Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease.

Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Intern Med. 2019 Sep 18. doi: 10.2169/internalmedicine.3555-19. [Epub ahead of print]

5.

Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy.

Ogasawara N, Saitoh S, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 Dec;49(12):1441-1450. doi: 10.1111/hepr.13418. Epub 2019 Oct 9.

PMID:
31373093
6.

Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy.

Suzuki H, Sezaki H, Suzuki F, Kasuya K, Sano T, Fujiyama S, Kawamura Y, Hosaka T, Akuta N, Saitoh S, Kobayashi M, Arase Y, Ikeda K, Suzuki Y, Kumada H.

Hepatol Res. 2019 Dec;49(12):1406-1413. doi: 10.1111/hepr.13415. Epub 2019 Aug 9.

PMID:
31347756
7.

[Dispatch Report on the 52nd Taiwan Society of Radiological Technologists (TWSRT 2019)].

Ishihara N, Sezaki H, Mizutani T, Watanabe Y, Matsumoto K.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2019;75(7):705-709. doi: 10.6009/jjrt.2019_JSRT_75.7.705. Japanese. No abstract available.

8.

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis.

Sano T, Akuta N, Suzuki F, Kasuya K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Intern Med. 2019 Sep 15;58(18):2657-2662. doi: 10.2169/internalmedicine.2604-18. Epub 2019 Jun 7.

9.

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.

Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH.

J Hepatol. 2019 Sep;71(3):473-485. doi: 10.1016/j.jhep.2019.04.017. Epub 2019 May 13.

PMID:
31096005
10.

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.

Sezaki H, Suzuki F, Hosaka T, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

J Gastroenterol. 2019 Oct;54(10):916-927. doi: 10.1007/s00535-019-01575-9. Epub 2019 Mar 22.

PMID:
30903385
11.

The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies.

Suzuki H, Kawamura Y, Kinowaki K, Akuta N, Kasuya K, Fujiyama S, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kumada H.

Intern Med. 2019 Jul 1;58(13):1891-1895. doi: 10.2169/internalmedicine.2374-18. Epub 2019 Feb 25.

12.

Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.

Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

Aliment Pharmacol Ther. 2019 Feb;49(4):457-471. doi: 10.1111/apt.15108. Epub 2019 Jan 20. Erratum in: Aliment Pharmacol Ther. 2019 Jul;50(2):234-235.

PMID:
30663078
13.

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.

Akuta N, Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 May;49(5):531-539. doi: 10.1111/hepr.13304. Epub 2019 Feb 6.

PMID:
30577089
14.

Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases.

Ohya K, Saitoh S, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kinowaki K, Fujii T, Kondo F, Kumada H.

Hepatol Res. 2019 Jun;49(6):711-717. doi: 10.1111/hepr.13295. Epub 2019 Jan 8.

PMID:
30537443
15.

Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study.

Sorin Y, Ikeda K, Kawamura Y, Fujiyama S, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Liver Cancer. 2018 Oct;7(4):323-334. doi: 10.1159/000487311. Epub 2018 Mar 14.

16.

Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan.

Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.

BMC Gastroenterol. 2018 Nov 6;18(1):165. doi: 10.1186/s12876-018-0900-1.

17.

Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.

Akuta N, Suzuki F, Sezaki H, Kobayashi M, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Clin Microbiol. 2019 Jan 2;57(1). pii: e01463-18. doi: 10.1128/JCM.01463-18. Print 2019 Jan.

18.

No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection.

Kawamura Y, Ikeda K, Shindoh J, Kobayashi Y, Kasuya K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Hashimoto M, Kumada H.

Hepatol Res. 2019 Feb;49(2):164-176. doi: 10.1111/hepr.13254. Epub 2018 Nov 6.

PMID:
30277295
19.

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.

Suzuki F, Hosaka T, Suzuki Y, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H.

J Gastroenterol. 2019 Feb;54(2):182-193. doi: 10.1007/s00535-018-1502-y. Epub 2018 Aug 22.

PMID:
30136216
20.

Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

Takeuchi Y, Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 Mar;49(3):256-263. doi: 10.1111/hepr.13242. Epub 2018 Sep 23.

PMID:
30125438
21.

Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.

Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2019 Jan;91(1):102-106. doi: 10.1002/jmv.25278. Epub 2018 Sep 3.

PMID:
30091810
22.

Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance.

Akuta N, Suzuki F, Kobayashi M, Hosaka T, Fujiyama S, Kawamura Y, Sezaki H, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 Oct;90(10):1586-1592. doi: 10.1002/jmv.25238. Epub 2018 Jul 10.

PMID:
29896794
23.

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis.

Kuwano T, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Intern Med. 2018 Sep 1;57(17):2511-2515. doi: 10.2169/internalmedicine.0585-17. Epub 2018 Mar 30.

24.

Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial.

Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K.

Hepatol Res. 2018 Sep;48(10):810-813. doi: 10.1111/hepr.13075. Epub 2018 Apr 24.

PMID:
29601141
25.

Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.

Ogata F, Akuta N, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 Jun;90(6):1087-1093. doi: 10.1002/jmv.25047. Epub 2018 Feb 26.

PMID:
29427443
26.

Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies.

Akuta N, Watanabe C, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.

Hepatol Commun. 2017 Feb 27;1(1):46-52. doi: 10.1002/hep4.1019. eCollection 2017 Feb.

27.

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.

Ohya K, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Kominami Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 May;90(5):919-925. doi: 10.1002/jmv.25023. Epub 2018 Jan 30.

PMID:
29315652
28.

Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome.

Fujiyama S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.

BMC Gastroenterol. 2017 Oct 25;17(1):112. doi: 10.1186/s12876-017-0668-8.

29.

Cholangiolocellular Carcinoma in a Young Patient Who Showed Sustained Virological Response after Treatment for Hepatitis C Virus Infection.

Osawa M, Saitoh S, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kinowaki K, Fujii T, Fukusato T, Kondo F, Kumada H.

Intern Med. 2017 Nov 15;56(22):3033-3040. doi: 10.2169/internalmedicine.9021-17. Epub 2017 Sep 25.

30.

Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.

Ogasawara N, Kobayashi M, Akuta N, Kominami Y, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Suzuki F, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H.

J Med Virol. 2018 Feb;90(2):313-319. doi: 10.1002/jmv.24950. Epub 2017 Sep 25.

PMID:
28906010
31.

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Dig Dis Sci. 2017 Oct;62(10):2932-2942. doi: 10.1007/s10620-017-4739-z. Epub 2017 Sep 7.

PMID:
28884320
32.

Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.

Osawa M, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Suzuki Y, Ikeda K, Kumada H.

J Med Virol. 2017 Dec;89(12):2144-2148. doi: 10.1002/jmv.24890. Epub 2017 Aug 31.

PMID:
28667756
33.

New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease.

Kawamura Y, Ikeda K, Arase Y, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H.

Intern Med. 2017;56(12):1459-1465. doi: 10.2169/internalmedicine.56.7830. Epub 2017 Jun 15.

34.

Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.

Ogata F, Kobayashi M, Akuta N, Osawa M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.

Oncology. 2017;93(2):92-98. doi: 10.1159/000470910. Epub 2017 Apr 28.

PMID:
28448999
35.

Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride.

Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K.

Hepatol Res. 2018 Jan;48(1):45-50. doi: 10.1111/hepr.12894. Epub 2017 Apr 19.

PMID:
28322485
36.

Synthesis of l-cysteine derivatives containing stable sulfur isotopes and application of this synthesis to reactive sulfur metabolome.

Ono K, Jung M, Zhang T, Tsutsuki H, Sezaki H, Ihara H, Wei FY, Tomizawa K, Akaike T, Sawa T.

Free Radic Biol Med. 2017 May;106:69-79. doi: 10.1016/j.freeradbiomed.2017.02.023. Epub 2017 Feb 9.

PMID:
28189853
37.

The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.

Sezaki H, Suzuki F, Hosaka T, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

Liver Int. 2017 Sep;37(9):1325-1333. doi: 10.1111/liv.13384. Epub 2017 Mar 17.

PMID:
28178397
38.

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.

Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2017 Jul;89(7):1248-1254. doi: 10.1002/jmv.24767. Epub 2017 Feb 27.

PMID:
28079269
39.

Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma.

Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Kobayashi M, Ikeda K, Kumada H.

BMC Gastroenterol. 2016 Dec 12;16(1):141.

40.

Potential of a no-touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas.

Kawamura Y, Ikeda K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Hepatol Res. 2017 Sep;47(10):1008-1020. doi: 10.1111/hepr.12838. Epub 2016 Dec 30.

PMID:
27862748
41.

Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.

Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2017 Jan;89(1):91-98. doi: 10.1002/jmv.24592. Epub 2016 Jun 8.

PMID:
27256744
42.

Acquired palatal groove and delayed oral feeding in preterm infants.

Enomoto M, Sezaki H, Muranishi R, Sato Y, Kikuchi S, Katayama Y, Takei A, Ikegami H, Sakuma M, Minami H.

Pediatr Int. 2017 Feb;59(2):171-175. doi: 10.1111/ped.13113. Epub 2016 Oct 19.

PMID:
27501257
43.

Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.

Suzuki F, Suzuki Y, Hosaka T, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H.

J Gastroenterol. 2017 May;52(5):641-651. doi: 10.1007/s00535-016-1270-5. Epub 2016 Oct 3.

PMID:
27699721
44.

Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.

Akuta N, Kobayashi M, Suzuki F, Sezaki H, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Oncology. 2016;91(6):341-347. Epub 2016 Oct 1.

PMID:
27694754
45.

Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.

Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2017 Mar;89(3):476-483. doi: 10.1002/jmv.24663. Epub 2016 Aug 23.

PMID:
27531586
46.

Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma.

Ikeda K, Kawamura Y, Kobayashi M, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Hepatol Res. 2017 Jun;47(7):632-640. doi: 10.1111/hepr.12782. Epub 2016 Sep 21.

PMID:
27487085
47.

Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.

Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2017 Feb;89(2):284-290. doi: 10.1002/jmv.24617. Epub 2016 Jul 6.

PMID:
27357737
48.

Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules.

Kawamura Y, Ikeda K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Hepatol Res. 2017 Mar;47(4):338-346. doi: 10.1111/hepr.12754. Epub 2016 Jul 12.

PMID:
27249401
49.

Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.

Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Kunimoto H, Sorin Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Kobayashi M, Ikeda K, Kumada H.

Hepatol Int. 2016 Jul;10(4):647-56. doi: 10.1007/s12072-016-9729-2. Epub 2016 Apr 13.

PMID:
27074850
50.

Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma.

Kunimoto H, Ikeda K, Sorin Y, Fujiyama S, Kawamura Y, Kobayashi M, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Oncology. 2016;90(3):167-75. doi: 10.1159/000443891. Epub 2016 Feb 23.

PMID:
26901157

Supplemental Content

Loading ...
Support Center